Bridgeway Capital Management LLC Invests $658,000 in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Bridgeway Capital Management LLC bought a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 140,000 shares of the company's stock, valued at approximately $658,000. Bridgeway Capital Management LLC owned about 0.26% of Fulcrum Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in FULC. BNP Paribas Financial Markets acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $38,000. Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $78,000. Cantor Fitzgerald L. P. acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $94,000. Zacks Investment Management acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $99,000. Finally, Intech Investment Management LLC raised its position in Fulcrum Therapeutics by 74.9% in the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after buying an additional 13,057 shares during the last quarter. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Price Performance

FULC stock traded up $0.28 during mid-day trading on Friday, reaching $6.88. The company had a trading volume of 1,040,199 shares, compared to its average volume of 967,666. The stock has a 50 day simple moving average of $3.69 and a two-hundred day simple moving average of $3.80. The company has a market capitalization of $371.38 million, a price-to-earnings ratio of -22.19 and a beta of 2.29. Fulcrum Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. On average, equities analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald raised Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research report on Thursday. HC Wainwright reissued a "neutral" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $4.50.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.